Alison M. Weppler
BC Cancer Agency(CA)University of British Columbia(CA)Peter MacCallum Cancer Centre(AU)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Polyomavirus and related diseases, Bacteriophages and microbial interactions, CAR-T cell therapy research
Most-Cited Works
- → Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study(2021)205 cited
- → Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders(2021)88 cited
- → Hematological immune related adverse events after treatment with immune checkpoint inhibitors(2021)86 cited
- → Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors(2020)80 cited
- → FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment(2020)69 cited
- → A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies(2019)51 cited